Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome's Leadership in NeuroscienceGlobeNewsWire • 03/28/22
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome TherapeuticsPRNewsWire • 03/28/22
Moore Kuehn, PLLC Encourages Investors of Axsome Therapeutics, Inc. To Contact Law FirmNewsfile Corp • 03/22/22
Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience ForumGlobeNewsWire • 03/11/22
Axsome Therapeutics, Inc.'s (AXSM) CEO Herriot Tabuteau on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/01/22
Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022GlobeNewsWire • 02/15/22
Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/11/22
Down 19% in 4 Weeks, Here's Why Axsome (AXSM) Looks Ripe for a TurnaroundZacks Investment Research • 01/17/22